Ten days ago, scientists who functionally cured sickle cell disease were handed a $3 million prize at a Hollywood gala. The political moment could not be more ironic.

The cure that politics almost buried

I think this is one of the most important medical stories of our lifetimes, and it is being drowned out by budget fights and culture war noise. Stuart Orkin of Harvard Medical School and Swee Lay Thein of the NIH just won the 2026 Breakthrough Prize in Life Sciences for research that turned sickle cell disease from a death sentence into a treatable condition. Their work directly enabled Casgevy, the first CRISPR-based medicine ever approved for any disease.

This is genuinely extraordinary. And the timing is a gut punch.

Here is what Orkin and Thein actually did. Thein mapped the trait of persistent fetal hemoglobin production to chromosome 2 and identified the gene BCL11A as the key player. Orkin then showed that BCL11A acts as the master off-switch for fetal hemoglobin after birth. Silence that switch, and the body keeps making the healthy fetal version of hemoglobin, which compensates for the defective adult form that causes sickle cell disease.

That insight, built over decades of curiosity-driven basic science, became the foundation for Casgevy. The therapy edits a patient's own blood stem cells using CRISPR, reactivates fetal hemoglobin production, and has eliminated painful vaso-occlusive crises for virtually all patients in clinical trials. Sickle cell disease affects approximately 100,000 people in the US alone, and millions more worldwide, predominantly in Africa, Asia, and the Mediterranean.

“There is no better story to refute those who doubt the value of science.”

— Stuart H. Orkin, Harvard Medical School, 2026 Breakthrough Prize Ceremony

Basic science is the part everyone wants to defund

I remember reading about sickle cell disease as a child and thinking it was simply one of those conditions medicine had given up on. The research that changed that did not start with a drug company chasing a profit. It started with Thein collecting families in Malaysia and the UK, tracing genetics across seven generations of one Indian family spanning multiple continents, trying to understand why some people with the disease had milder symptoms. That is what basic science looks like. It is slow, it is unglamorous, and it is exactly what budget-cutters target first.

The political context here is not subtle. The Trump administration has proposed cutting $16 billion from the Department of Health and Human Services budget, and the NIH, where Thein works, sits squarely in the crosshairs. The National Science Foundation has been proposed for leadership by a former acting CDC director with no research background. The University of California system, which has produced 15 Breakthrough Prize winners, is watching federal investment erode in real time.

The Orkin-Thein story is a direct rebuttal to every politician who calls basic research wasteful spending.

The good news is real, but the access problem is not solved

Here is where I will give the critics their due, because they are not entirely wrong. Casgevy is a functional cure, but it costs millions of dollars per patient. The treatment process can take up to a year. It requires harsh chemotherapy to clear the bone marrow before the gene-edited stem cells can take root. Thein herself has said the process is physically grueling. And sickle cell disease predominantly affects people in Africa, Asia, and the Mediterranean, where the infrastructure for this treatment simply does not exist.

So yes, the access gap is real and it is serious. But that critique does not cancel the achievement. It demands a policy response, not a dismissal of the science. The answer to a cure that is too expensive is not to stop funding the research that produces cures. It is to build the political will to make those cures accessible.

Scientists are already working on an in-vivo approach that would inject the gene-editing tool directly into the body, bypassing the grueling stem cell extraction process entirely. That next generation of therapy is only possible because of the foundational work Orkin and Thein did. Cut the funding pipeline now and you do not just lose today's research. You lose the cures that would have existed in 2035.

Hollywood gave scientists a standing ovation, Washington gave them a budget cut

The 2026 Breakthrough Prize ceremony at Barker Hangar in Santa Monica on April 18 was, by all accounts, genuinely moving. Thein recalled playing on old railway tracks in Malaysia as a child, never imagining she would stand on a Hollywood stage accepting a $3 million prize for reshaping medicine. Orkin reflected on five decades of research. The room gave them a standing ovation.

Meanwhile, in Washington, the same week, associations representing universities were asking Congress to appropriate $9 billion for NASA science just to keep existing programs alive. The Department of Energy's Office of Science is being restructured. The CDC has had its confirmed director ousted after less than a month. This is not a government that is building toward the next Breakthrough Prize. It is one that is actively dismantling the conditions that make such prizes possible.

I do not buy the argument that private philanthropy can fill the gap. The National Science Foundation has been a principal supporter of the Kavli Institute for Theoretical Physics since 1979. The NIH funded the lab where Thein made her key discoveries. Sergey Brin and Mark Zuckerberg can write big checks for a gala, but they cannot replicate the sustained, distributed, decades-long investment that only governments can provide.

Would you trust a country that defunds its own scientists to lead the next medical revolution?